Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33996610/
doi: 10.3389/fonc.2021.680191. 1 Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Free PMC article Background: The association between driver genes...
Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33968765/
Although immune checkpoint inhibitors (ICIs) have shown remarkable benefit for treatment of advanced non-small lung cancer (NSCLC), only a minority of patients can achieve durable responses and the most patients...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Findings • In the current study, researchers mined The Cancer Genome Atlas (TCGA) and discovered that patients with the coexisting NOTCH+/co-DDR+ pathway exhibited a higher tumor mutation burden (TMB) and Show More
Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33976268/
Among non-small cell lung cancer (NSCLC) patients with therapeutically targetable tumor mutations in epidermal growth factor receptor (EGFR), not all patients respond to targeted therapy. Combining circulating-tumor DNA (ctDNA), clinical...
Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33973139/
Variants in the epidermal growth factor receptor (EGFR) gene are recognized as predictors of therapy response and are correlated with progression-free and overall survival in non-small cell lung cancer (NSCLC)...
Non-Small-Cell Lung Cancer: New Rare Targets-New Targeted Therapies-State of The Art and Future Directions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33921237/
Lung cancer is the most common cause of cancer-related death worldwide, and the prognosis for stage IV remains poor. The presence of genetic alterations in tumor cells, such as EGFR...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • The authors of the current review highlighted therapeutic targets in NSCLC, as well as drugs that against NTRK, RET, MET or HER2 gene alterations. In the aggregate, 50% Show More